Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07532902) titled 'A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer' on April 8.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Memorial Sloan Kettering Cancer Center
Condition:
Diffuse Pleural Mesothelioma
Gastroesophageal Carcinoma
Urothelial Carcinoma
Intervention:
Drug: BMS-986504
Drug: Ipilimumab
Drug: Nivolumab
Drug: 5-FU
Drug: Leucovorin
Drug: Oxaliplatin
Drug: Gemcitabine
Recruitment Status: Recruiting
Phase: Phase 1
Date of First Enrollment: Ap...